To explore whether proxies of premorbid structural reserve—intracranial volume (ICV) and spinal cervical canal area (SCCA)—influence long-term disability accumulation in multiple sclerosis (MS), specifically through progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW).
Methods:
We included 253 patients with relapsing-onset MS, ⩾5-year follow-up from first demyelinating event (FDE), and available 3D T1-weighted magnetic resonance imaging (MRI) scan enabling estimation of ICV and SCCA. To account for PIRA and RAW co-occurrence in the same individuals, we used negative binomial regression to estimate adjusted event rate ratios (adj.-ERRs) and competing risk models to derive subdistribution hazard ratios (SHRs) for PIRA and RAW events.
Results:
Over a median 17-year follow-up, higher SCCA was associated with fewer PIRA events (adj.-ERR = 0.74, p = 0.014) and delayed PIRA onset (SHR = 0.50, p = 0.05), while larger ICV was associated with fewer RAW events (adj.-ERR = 0.70, p = 0.033) and both later occurrence (SHR = 0.41, p = 0.02) and older age at RAW (SHR = 0.30, p = 0.002). Patients with high combined reserve (both larger ICV and SCCA) reached EDSS ⩾ 6.0 later (hazard ratio (HR) = 0.33, p = 0.025) and at older age (HR = 0.37, p = 0.045) than those with low reserve.
Conclusion:
Pre-morbid structural reserve mitigates the MS-related disability accrual, supporting the integration of ICV and SCCA into prognostic models as markers of neuroanatomical resilience.
MüllerJCagolALorscheiderJ, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: A systematic review. JAMA Neurol2023; 80(11): 1232–1245.
2.
CalabreseMPreziosaPScalfariA, et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol2024; 96(1): 1–20.
3.
SternYBarnesCAGradyC, et al. Brain reserve, cognitive reserve, compensation, and maintenance: Operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging2019; 83: 124–129.
4.
SumowskiJFRoccaMALeavittVM, et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology2014; 82(20): 1776–1783.
5.
SumowskiJFRoccaMALeavittVM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology2016; 86(21): 2006–2009.
6.
JohnNLiYDe AngelisF, et al. Brain reserve and physical disability in secondary progressive multiple sclerosis. BMJ Neurol Open2024; 6(2): e000670.
7.
Sastre-GarrigaJRoviraAGarcía-VidalA, et al. Spinal cord reserve in multiple sclerosis. J Neurol Neurosurg Psychiatry2023; 94(7): 502–510.
8.
Mongay-OchoaNParetoDAlberichM, et al. Association of the cervical canal area with disability and progression in people with multiple sclerosis. Neurology2025; 104(1): e210136.
9.
PetraccaMRuggieriSNistriR, et al. Brain reserve and timing of clinical onset in multiple sclerosis. Mult Scler2024; 30(10): 1290–1295.
10.
MüllerJSharminSLorscheiderJ, et al. Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis. JAMA Neurol2025; 82: 614–625.
11.
WarrierVStaufferEMHuangQQ, et al. Genetic insights into human cortical organization and development through genome-wide analyses of 2,347 neuroimaging phenotypes. Nat Genet2023; 55(9): 1483–1493.
12.
SumowskiJFRoccaMALeavittVM, et al. Brain reserve and cognitive reserve in multiple sclerosis: What you’ve got and how you use it. Neurology2013; 80(24): 2186–2193.
13.
Mongay-OchoaNParetoDAlberichM, et al. Validation of a new semiautomated segmentation pipeline based on the spinal cord toolbox DeepSeg algorithm to estimate the cervical canal area. AJNR Am J Neuroradiol2023; 44(7): 867–872.
14.
ProsperiniLRuggieriSHaggiagS, et al. Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context. Mult Scler2024; 30(10): 1309–1321.
15.
LizakNMalpasCBSharminS, et al. Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. JAMA Neurol2020; 77(11): 1398–1407.
16.
WijnandsJMAKingwellEZhuF, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: A matched cohort study. Lancet Neurol2017; 16(6): 445–451.
17.
BjornevikKMungerKLCorteseM, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol2020; 77(1): 58–64.
18.
TurCRoccaMA. Progression independent of relapse activity in multiple sclerosis: Closer to solving the pathologic puzzle. Neurology2024; 102(1): e207936.
19.
LublinFDHäringDAGanjgahiH, et al. How patients with multiple sclerosis acquire disability. Brain2022; 145(9): 3147–3161.
20.
LucchinettiCBrückWParisiJ, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. Brain1999; 122(Pt12): 2279–2295.
21.
KammaELasisiWLibnerC, et al. Central nervous system macrophages in progressive multiple sclerosis: Relationship to neurodegeneration and therapeutics. J Neuroinflammation2022; 19(1): 45.
22.
CagolABenkertPMelie-GarciaL, et al. Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS. Neurology2024; 102(1): e207768.
23.
Ocampo-PinedaMCagolABenkertP, et al. White matter tract degeneration in multiple sclerosis patients with progression independent of relapse activity. Neurol Neuroimmunol Neuroinflamm2025; 12(3): e200388.
24.
MarastoniDColatoEFoschiM, et al. Intrathecal inflammatory profile and gray matter damage predict progression independent of relapse activity in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2025; 12(4): e200399.
25.
LauererMMcGinnisJBussasM, et al. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry2023; 95(1): 37–43.
26.
BischofAPapinuttoNKeshavanA, et al. Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. Ann Neurol2022; 91(2): 268–281.
27.
GiovannoniGCutterGSormaniMP, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord2017; 12: 70–78.
28.
KremenchutzkyMRiceGPBaskervilleJ, et al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain2006; 129(Pt. 3): 584–594.
29.
RobinCRollotFLefortM, et al. Use of disease-modifying therapies in patients with late-onset multiple sclerosis. Neurology2025; 105(3): e213744.
30.
CagolASchaedelinSOcampo-PinedaM, et al. Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: An observational study in the Swiss Multiple Sclerosis Cohort. J. Neurol2025; 272(8): 491.
31.
MarrieRA. Comorbidity in multiple sclerosis: Implications for patient care. Nat Rev Neurol2017; 13(6): 375–382.
32.
Van LoenhoudACGrootCVogelJW, et al. Is intracranial volume a suitable proxy for brain reserve?Alzheimers Res Ther2018; 10(1): 91.
33.
PapinuttoNBakshiRBischofA, et al. Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1-weighted brain MRI acquisitions. Magn Reson Med2018; 79(3): 1595–1601.
